"Industry rights" document from FDA to quell fears of retaliation will be written, Kessler assures Sen. Gregg.
Executive Summary
FDA "INDUSTRY RIGHTS" DOCUMENT ON RETALIATION/DISPUTE RESOLUTION will be developed by the agency's Chief Mediator and Ombudsman Office, FDA Commissioner Kessler said in a June 29 letter to Sen. Gregg (R-N.H.). "In order to enhance the industry's knowledge and use" of the Ombudsman's office, which Kessler described as a "resource" for problem resolution between industry and the agency, the commissioner has directed the office "to prepare a document that will outline industry's rights and describe the agency's processes for both retaliation and dispute resolution."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth